Time to end the non-inferiority complex?

被引：1
|
作者：
Julious, Steven A. [1 ]
机构：
[1] Univ Sheffield, Med Stat Grp, Hlth Serv Res, Sheffield S1 4DA, S Yorkshire, England
来源：
PHARMACEUTICAL STATISTICS | 2011年 / 10卷 / 05期
关键词：
STATISTICAL-METHODS; MARGIN;
D O I：
10.1002/pst.519
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：393 / 394
页数：2
相关论文
共 50 条
  • [41] Current issues in non-inferiority trials
    Flerning, Thomas R.
    STATISTICS IN MEDICINE, 2008, 27 (03) : 317 - 332
  • [42] Two-stage winner designs for non-inferiority trials with pre-specified non-inferiority margin
    Wang, Pin-Wen
    Lu, Shou-En
    Lin, Yong
    Shih, Weichung J.
    Lan, K. K. Gordon
    JOURNAL OF STATISTICAL PLANNING AND INFERENCE, 2017, 183 : 44 - 61
  • [43] Using non-inferiority test of proportions in design of randomized non-inferiority trials with time-to-event endpoint with a focus on low-event-rate setting
    Ji, Lingyun
    Alonzo, Todd A.
    CLINICAL TRIALS, 2024,
  • [44] Improving the reporting of non-inferiority trials by incorporating non-efficacy benefits: not all non-inferiority trials are created equal
    Sergio A. Acuna
    Fahima Dossa
    Tyler R. Chesney
    European Journal of Epidemiology, 2021, 36 : 1097 - 1101
  • [45] NON-INFERIORITY STUDIS: SENSE OR NON-SENSE
    Lesaffre, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 49 - 49
  • [46] Non-inferiority trials with time-to-event data: clarifying the impact of censoring
    Choi, Jaeun
    Xue, Xiaonan
    Kim, Mimi
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2024, 34 (02) : 222 - 239
  • [47] IS THERE A CONSENSUS REGARDING CLINICALLY RELEVANT NON-INFERIORITY MARGINS USED FOR KEY ONCOLOGY ENDPOINTS IN NON-INFERIORITY ONCOLOGY TRIALS?
    Hashim, M.
    He, J.
    Hu, P.
    Soikkeli, F.
    Gebregergish, S.
    Heeg, B.
    Lam, A.
    VALUE IN HEALTH, 2018, 21 : S228 - S228
  • [48] Sample size estimation for non-inferiority trials of time-to-event data
    Crisp, Adam
    Curtis, Paula
    PHARMACEUTICAL STATISTICS, 2008, 7 (04) : 236 - 244
  • [49] Non-inferiority trials in breast and non-small cell lung cancer: Choice of non-inferiority margins and other statistical aspects
    Saad, Everardo D.
    Buyse, Marc
    ACTA ONCOLOGICA, 2012, 51 (07) : 890 - 896
  • [50] RESPONSE TO "REASSESSING CLAIMS OF NON-INFERIORITY OF DAPTOMYCIN"
    Shaw, George J.
    Lindsell, Christopher J.
    JOURNAL OF EMERGENCY MEDICINE, 2017, 52 (04): : 584 - 585
12345